Date: 3/16	/23
Your Name:	JAY M. LEE
Manuscript Title	: Clinical and economic outcomes associated with lymph node examination status in
early stage non	small cell lung cancer: a real-world US study using the SEER-Medicare linked database
Manuscrint nur	pher (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initia	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Genentech Roche	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	Advisory Board – AstraZeneca, Bristol Myers Squibb, Foundation Medicine Institute, Genentech, Merck, Novartis, Regeneron	

		Pharmaceuticals, Roche	
3	Royalties or licenses	xNone	
4	Consulting fees	Consultant— AstraZeneca, Bristol Myers Squibb, Foundation Medicine Institute, Genentech, Merck, Novartis, Regeneron Pharmaceuticals, Roche	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None AstraZeneca, Bristol Myers Squibb, DAVA Oncology, ecancer, Genentech, Medscape, Roche, Targeted Oncology	
6	Payment for expert testimony	_xNone	
7	Support for attending meetings and/or travel	AstraZeneca, Bristol Myers Squibb, Foundation Medicine Institute, Genentech, Merck, Novartis, Regeneron Pharmaceuticals, Roche	
8	Patents planned, issued or pending	UCLA	
9	Participation on a Data Safety Monitoring Board or Advisory Board	xNone	
10		xNone	

	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid		
11	Stock or stock options	Moderna	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	xNone	
13	Other financial or non- financial interests	xNone	

Research support for this study provided by Genentech Inc, a member of the Roche Group; participation on an advisory board from AstraZeneca, Bristol Myers Squibb, Foundation Medicine Institute, Genentech, Merck, Novartis, Regeneron Pharmaceuticals, and Roche consultant fees from AstraZeneca, Bristol Myers Squibb, Foundation Medicine Institute, Genentech, Merck, Novartis, Regeneron Pharmaceuticals, and Roche; Payment or honoraria from AstraZeneca, Bristol Myers Squibb, Dava Oncology, eCancer, Genentech, Medscape, Roche, and Targeted Oncology; support for attending meetings or travel from AstraZeneca, Bristol Myers Squibb, Foundation Medicine Institute, Genentech, Merck, Novartis, Regeneron Pharmaceuticals, and Roche; and patents planned, issued or pending from University of California, Los Angeles; stock or stock options from Moderna.

Please place an "X" next to the following statement to indicate your agreement:

_x__ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date:_03/16/2023	
Your Name: Tu My To	
Manuscript Title:_Clinical and e	economic outcomes associated with lymph node examination status in early stage
non-small cell lung cancer: A re	al-world US study using the SEER-Medicare linked database
Manuscript number (if known):	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> manuscript only.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initia	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Genentech	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert	None	
0	testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
11	Stock or stock options	Roche	Stock and stock options
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non- financial interests	Employment with Genentech, Inc	

Research support for this study provided by Genentech Inc, a member of the Roche Group; employee and stockholder of Genentech Inc, a member of the Roche Group.

Please place an "X" next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date: 03-16-2023
Your Name: Shu Wang
Manuscript Title: Clinical and economic outcomes associated with lymph node examination status in early stage non-

small cell lung cancer: A real-world US study using the SEER-Medicare linked database

Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initia	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Genentech	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	
	testimony		
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy		
4.4	group, paid or unpaid	NI.	
11	Stock or stock options	None	
12	Descipt of aguinment	None	
12	Receipt of equipment, materials, drugs, medical	None	
	writing, gifts or other		
	services		
13	Other financial or non-	Genesis Research	Employment.
13	financial interests	252313 11.23241 011	Employment
	ariolar irred ests		

employee of Genesis Research, which received research funding for this study from Genentech Inc, a member of the Roche Group; Research support for this study provided by Genentech Inc, a member of the Roche Group

Please place an "X" next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date:_03/16/2023				
Your Name:	_Chia-Wei Lin			
Manuscript Tit	le:_Clinical and economic outcomes associated with lymph node examination status in early stage			
non-small cell le	ung cancer: A real-world US study using the SEER-Medicare linked database			
Manuscript nui	mber (if known):			

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initia	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Genentech	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
11	Stock or stock options	Roche	Stock and stock options
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non- financial interests	Employment with Genentech, Inc	

Research support for this study provided by Genentech Inc, a member of the Roche Group; employee and stockholder of Genentech Inc, a member of the Roche Group.

Please place an "X" next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date: M	arch 1	6, 2023
---------	--------	---------

Your Name: Ann Johnson, MMSc

Manuscript Title: Clinical and economic outcomes associated with lymph node examination status in early stage non-small cell

lung cancer: A real-world US study using the SEER-Medicare linked database Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initia	planning of the work
1	All support for the present	Genentech	Employee
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	None	
4	Consulting fees	None	

		1	
5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	
	testimony		
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	Employment with	
	financial interests	Genentech, Inc	

Genentech, Inc, employe	ee
This work was support	ed by Genentech Inc, a member of the Roche Group.

Please place an "X" next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date: 19-March-2023 Your Name: Craig S. Meyer

Manuscript Title: Clinical and economic outcomes associated with lymph node examination status in early stage non-small

cell lung cancer: A real-world US study using the SEER-Medicare linked database

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Time frame: Since the initialNone Genentech- Roche	pranning of the work
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_XNone	
3	Royalties or licenses	XNone	

	C III C	V None	
4	Consulting fees	XNone	
5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or	_XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	Stock Holder Roche
			Stock Holder Johnson&Johnson
12	Receipt of equipment,	XNone	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	Former employment with	
	financial interests	Genentech, Inc; current	
		employment with Janssen	
		<u>Pharmaceuticals</u>	

Employed by Genentech during study as Senior Data Scientist.
Stockholder in Roche and Johnson & Johnson.

This work was supported by Genentech Inc, a member of the Roche Group.

Please place an "X" next to the following statement to indicate your agreement:

__X_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

e:3/15/2023					
Name:Janet Lee					
uscript Title: Clinical	and economic outcomes a	ssociated with lymph node examination status in early stage			
on-small cell lung cancer: A real-world US study using the SEER-Medicare linked database					
uscript number (if known):					
eed to the content of your noises whose interests may be ansparency and does not noisenship/activity/interest, it following questions apply to	nanuscript. "Related" mea affected by the content of ecessarily indicate a bias. t is preferable that you do	f the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a so.			
e epidemiology of hyperterication, even if that medication are the support all supports al	nsion, you should declare a stion is not mentioned in the port for the work reported	defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive he manuscript. I in this manuscript without time limit. For all other items,			
	Name all entities with	Specifications/Comments			
		(e.g., if payments were made to you or to your			
	-	institution)			
	-	,			
	needed)				
	Time frame: Since the initia	al planning of the work			
All support for the present		·			
medical writing, article					
processing charges, etc.)					
No time limit for this item.					
	Time frame: pas	t 36 months			
Grants or contracts from	None				
					
	None				
no parties of ficefises					
Consulting fees	None				
	Name: Janet Lee Clinical small cell lung cancer: A resuscript number (if known): the interest of transparency, ted to the content of your name ies whose interests may be ansparency and does not nationship/activity/interest, it following questions apply the uscript only. The epidemiology of hypertelection, even if that medical em #1 below, report all suptime frame for disclosure is an anuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	cuscript Title: Clinical and economic outcomes a small cell lung cancer: A real-world US study using the suscript number (if known):			

5	Payment or honoraria for	None		
	lectures, presentations,			
	speakers bureaus,			
	manuscript writing or			
	educational events			
6	Payment for expert	None		
	testimony			
7	Support for attending	None		
	meetings and/or travel			
8	Patents planned, issued or	None		
U	pending			
	perioning			
9	Participation on a Data	None		
,	Safety Monitoring Board or			
	Advisory Board			
10	Leadership or fiduciary role	None		
10	in other board, society,			
	committee or advocacy			
	group, paid or unpaid			
11	Stock or stock options	Roche	Stock and stock options	
12	Receipt of equipment,	None		
	materials, drugs, medical			
	writing, gifts or other			
	services			
13	Other financial or non-	Employment with		
	financial interests	Genentech, Inc		
		CI: . C:		

During the time of this work, I was an employee paid with salary and stock/options by Genentech/Roche
This work was supported by Genentech Inc, a member of the Roche Group.

Please place an "X" next to the following statement to indicate your agreement:

__X_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.